Young Nuclear Medicine Physician Academy for RLT

Dear Doctor,

Radioligand therapy (RLT) is becoming an important pillar of cancer care globally. However, several challenges faced by nuclear medicine physicians need to be overcome. Nuclear medicine physicians were traditionally involved in diagnostic medicine, with little patient contact. RLT involves directly treating patients which often have various co-morbidities. The therapy itself also presents various complex regulatory challenges in Switzerland, potentially limiting widespread adoption. Finally, there is a need to attract younger physicians to this area of medicine because the current workforce is not big enough to treat all patients in the future. The objective of this event is therefore to train and connect young nuclear medicine physicians interested in RLT.

Come and help us shape the future of cancer care in Switzerland!

We look forward to your attendance.

October 31, 2025
sitem-insel

3 SGNM CME credits

2 Travel Awards - Apply now!

This year we will be awarding two travel awards to attend the biggest European Medical Oncology (ESMO) and Nuclear Medicine (EANM) Conferences:

EANM 2025 Annual Congress, October 4th to 8th, Barcelona, Spain

ESMO Congress 2025, October 17th to 21st, Berlin, Germany

What can you expect from the award?

  • Mentorship

  • Travel, accommodation and registration fees*

*while adhering to 33% co-payment rule as outlined in Swiss Ordinance VITH

You must fulfill at least 2 of the following criteria:

  • Have a nuclear medicine FMH title

  • Be an experienced speaker involved in previous events

  • Have published research in RLT/nuclear medicine

  • Have been an investigator on clinical trials

  • Have treated a significant number of patients with RLT

  • Have been involved in local/international guidelines

  • Are a board member of a medical society

Apply by August 15th

Send your CV, motivation letter & letter of recommendation to gabriela.fosado_wyhooge@novartis.com. The steering committee will select the winners based on academic standing (i.e. the criteria listed above). Applicants should be in residency or have completed their FMH title in the last 5 yrs from the application deadline. Travel award winners will have the privilege of presenting their highlights of ESMO/EANM at this event under the mentorship of Prof Schaefer.

Steering Committee

Valentina Garibotto
Prof Dr

HUG, Geneva

Magdalena Kulgawczuk
Dr

Inselspital, Bern

Aurelius Omlin
PD Dr

Onkozentrum, Zürich

Niklaus Schaefer
Prof Dr

CHUV, Lausanne

Michael Wissmeyer
PD Dr

Bürgerspital Solothurn

Schedule

15:00 - 15:15
Welcome & Introduction

Chairs: Prof Dr Schaefer & PD Dr Omlin

15:05 - 15:20
Radioligand Therapy in 2025 in Switzerland: An update

PD Dr Paone, EOC Bellinzona

15:20 - 15:35
Open questions from an oncologist’s perspective

Prof Lorch, USZ Zürich

15:35 - 16:00
Discussion
16:00 - 16:30
Networking
16:30 - 16:50
Case study 1 (frequent challenges)

Chairs: PD Dr Wissmeyer & Prof Lorch

Dr Bianchetto Wolf & Dr Colarusso

16:50 - 17:10
Case study 2 (frequent challenges)

Dr Kulgawczuk & PD Dr Omlin

17:10 - 17:30
Networking time
17:30 - 18:10
Statistics in Clinical Studies

Chairs: Prof Dr Garibotto & PD Dr Omlin

Dr Hayoz

18:10 - 18:30
Young Nucl Med: ESMO highlights

TBD

18:30 - 18:50
Young Nucl Med: EANM highlights

TBD

18:50 - 19:00
Closing followed by Apero

Location

sitem-insel

Switzerland
3010 Bern

Registration